UNSPSC 51361702: Ibrotamide

This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 09C8B34RDF. European Medicines Agency schedules Ibrotamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08095MIG. Ibrotamide generally arises in the molecular formula C7H14BRNO. The term IBROTAMIDE is an International Non-Proprietary Name or INN. IBROTAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule ibrotamide under HS 29241900 and SITC 51471. As of Q4 2014, IBROTAMIDE remains the US FDA Preferred Term for this commodity. Ibrotamide bears US NLM identifiers UMLS ID C2827189 and NCI Concept Code C83773. SMILES: BRC(C(C)C)(CC)C(=O)N.

UNSPSC 51361702 Ibrotamide is a Commodity code that in recent state and local procurement activity captures purchases of naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through government health and human services channels. The code spans pharmaceutical products procured by state departments, county health agencies, and cooperative purchasing alliances to support community health initiatives, pharmacy benefit programs, and public health response operations. Issuing bodies range from county health departments (Seminole County, Florida) to state health and human services commissions (Texas HHS) to multi-state cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across participating jurisdictions including Oregon). The recent solicitation activity shows state and local governments buying specific pharmaceutical commodities either as direct purchases with fixed quantities and delivery schedules or through cooperative contracts that establish pricing frameworks and authorized distribution channels.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023 (note: date discrepancy in source; posted June 2026, deadline states July 2023), structured as a fixed-fee two-year contract with one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs and therapeutic pharmacy initiatives outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative, issued RFP S1070000015802 in January 2026 for multi-state generic pharmaceutical and OTC product contracts effective July 1, 2026, with proposals due March 26, 2026, requiring vendors to work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and supply products with specific National Drug Codes and cGMP and DSCSA certifications.